Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47,856 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity.
Chen D, Barsoumian HB, Fischer G, Yang L, Verma V, Younes AI, Hu Y, Masropour F, Klein K, Vellano C, Marszalek J, Davies M, Cortez MA, Welsh J. Chen D, et al. Among authors: hu y. J Immunother Cancer. 2020 Jun;8(1):e000289. doi: 10.1136/jitc-2019-000289. J Immunother Cancer. 2020. PMID: 32581056 Free PMC article.
Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials.
Chen D, Menon H, Verma V, Guo C, Ramapriyan R, Barsoumian H, Younes A, Hu Y, Wasley M, Cortez MA, Welsh J. Chen D, et al. Among authors: hu y. J Immunother Cancer. 2020 Jan;8(1):e000492. doi: 10.1136/jitc-2019-000492. J Immunother Cancer. 2020. PMID: 31996395 Free PMC article. Clinical Trial.
SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.
Chen D, Barsoumian HB, Yang L, Younes AI, Verma V, Hu Y, Menon H, Wasley M, Masropour F, Mosaffa S, Ozgen T, Klein K, Cortez MA, Welsh JW. Chen D, et al. Among authors: hu y. Cancer Immunol Res. 2020 Jul;8(7):883-894. doi: 10.1158/2326-6066.CIR-19-0744. Epub 2020 Apr 16. Cancer Immunol Res. 2020. PMID: 32299915 Free PMC article.
Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity.
Younes AI, Barsoumian HB, Sezen D, Verma V, Patel R, Wasley M, Hu Y, Dunn JD, He K, Chen D, Menon H, Masrorpour F, Gu M, Yang L, Puebla-Osorio N, Cortez MA, Welsh JW. Younes AI, et al. Among authors: hu y. Transl Oncol. 2021 Feb;14(2):100983. doi: 10.1016/j.tranon.2020.100983. Epub 2020 Dec 16. Transl Oncol. 2021. PMID: 33340886 Free PMC article.
A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model.
Hu Y, Paris S, Barsoumian H, Abana CO, He K, Sezen D, Wasley M, Masrorpour F, Chen D, Yang L, Dunn JD, Gandhi S, Nguyen QN, Cortez MA, Welsh JW. Hu Y, et al. J Nanobiotechnology. 2021 Dec 11;19(1):416. doi: 10.1186/s12951-021-01163-1. J Nanobiotechnology. 2021. PMID: 34895262 Free PMC article.
Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer.
Hu Y, Paris S, Bertolet G, Barsoumian HB, He K, Sezen D, Chen D, Wasley M, Silva JD, Mitchell JA, Voss TA, Masrorpour F, Leyton CK, Yang L, Leuschner C, Puebla-Osorio N, Gandhi S, Nguyen QN, Cortez MA, Welsh JW. Hu Y, et al. J Nanobiotechnology. 2022 Sep 19;20(1):417. doi: 10.1186/s12951-022-01621-4. J Nanobiotechnology. 2022. PMID: 36123677 Free PMC article.
Pulsed radiotherapy to mitigate high tumor burden and generate immune memory.
Sezen D, Barsoumian HB, He K, Hu Y, Wang Q, Abana CO, Puebla-Osorio N, Hsu EY, Wasley M, Masrorpour F, Wang J, Cortez MA, Welsh JW. Sezen D, et al. Among authors: hu y. Front Immunol. 2022 Oct 6;13:984318. doi: 10.3389/fimmu.2022.984318. eCollection 2022. Front Immunol. 2022. PMID: 36275767 Free PMC article.
NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model.
Hu Y, Paris S, Bertolet G, Barsoumian HB, Wang Q, Da Silva J, Patel NB, Nguyen N, Doss DJ, Huang A, Hsu E, Leyton CSK, Voss TA, Masrorpour F, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Hu Y, et al. Front Immunol. 2022 Nov 3;13:1022011. doi: 10.3389/fimmu.2022.1022011. eCollection 2022. Front Immunol. 2022. PMID: 36405757 Free PMC article.
47,856 results
You have reached the last available page of results. Please see the User Guide for more information.